ISSN: 2475-6296

Review Article

Journal of Clinical & Experimental Immunology

Addressing the Challenges of PD-1 Targeted Immunotherapy in Cancer Treatment

Mohd Mustafa[1], Safia Habib[2], Irfan Qadir Tantry[3] and Sidra Islam[4]*

[1,2]*Department of Biochemistry, J.N. Medical College, Aligarh Muslim University, Aligarh, India*

[3]*Department of Biochemistry, School of Biological Sciences, University of Kashmir, Srinagar, India.*

[4]*Department of Pathology, Case Western Reserve University, Cleveland, Ohio, 44120, USA.*

***Corresponding Author**

Sidra Islam, Department of Pathology, Case Western Reserve University, Cleveland, Ohio, 44120, USA.

Submitted: 2024, Mar 18; **Accepted:** 2024, Apr 11; **Published:** 2024, Apr 29

Citation: Mustafa, M., Habib, S., Tantry, I. Q., Islam, S. (2024). Addressing the Challenges of PD-1 Targeted Immunotherapy in Cancer Treatment. *J Clin Exp Immunol, 9*(1), 01-03.

Abstract

Background: *Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis have revolutionized cancer treatment, demonstrating remarkable clinical efficacy across multiple malignancies. However, their broader applicability and therapeutic potential remain constrained by several challenges.*

Objective: *This review aims to provide a comprehensive overview of the current challenges associated with PD-1 targeted immunotherapy, encompassing resistance mechanisms, patient selection, toxicity management, and the development of novel combination strategies.*

Methods: *A comprehensive literature search was conducted across PubMed, Embase, and Web of Science databases to identify and critically analyze studies investigating the challenges and limitations of PD-1 targeted immunotherapy in cancer treatment.*

Results: *The primary challenges identified include: (1) Intrinsic and acquired resistance mechanisms, such as alterations in antigen presentation, tumor microenvironment factors, and immune cell dysfunction; (2) Lack of reliable predictive biomarkers for patient selection and response monitoring; (3) Immune-related adverse events and their effective management; (4) Optimization of combination regimens with other immunotherapies, targeted therapies, or conventional treatments; (5) Financial and accessibility barriers limiting the broader implementation of immunotherapy.*

Conclusion: *PD-1 targeted immunotherapy has transformed cancer treatment, addressing the current challenges is imperative to maximize its therapeutic potential and broaden its applicability. Ongoing research efforts focused on elucidating resistance mechanisms, developing predictive biomarkers, managing toxicities, and exploring novel combination strategies hold promise for overcoming these limitations. Interdisciplinary collaborations and continued investment in immunotherapy research are essential to ensure that the benefits of these groundbreaking therapies are accessible to a wider patient population.*

Keywords: PD-1 Targeted Immunotherapy, Resistance Mechanisms, Patient Selection Combination Strategies, Toxicity Management.

1. Introduction

The advent of immune checkpoint inhibitors, particularly those targeting the programmed cell death protein 1 (PD-1) and its ligand PD-L1, has resulted in a paradigm shift in cancer treatment. By unleashing the body's immune system to recognize and eliminate cancer cells, PD-1 targeted immunotherapy has demonstrated remarkable clinical efficacy across different types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. However, despite these encouraging developments, several challenges persist, hindering the broader applicability and optimising the therapeutic potential of these agents [1].

One of the most significant challenges is the development of resistance mechanisms, which can be broadly categorized as intrinsic or acquired resistance. Certain tumors may exhibit intrinsic resistance to PD-1 blockade, rendering these therapies. This resistance can arise from various factors, such as alterations in antigen presentation machinery, preventing effective recognition of tumor cells by T cells. Additionally, an immunosuppressive tumor microenvironment characterized by the presence of regulatory T cells, myeloid-derived suppressor

cells, and immunosuppressive cytokines can contribute to intrinsic resistance. Furthermore, a lack of tumor-infiltrating lymphocytes (TILs) or dysfunctional TILs unable to mount an effective anti-tumor response may also play a role in intrinsic resistance [2].

Even in patients who initially respond to PD-1 targeted immunotherapy, acquired resistance can develop over time, leading to disease progression. Potential mechanisms underlying acquired resistance include the upregulation of alternative immune checkpoints, compensating for PD-1 blockade [3]. Additionally, the loss of tumor antigen expression or impaired antigen presentation can render tumor cells "invisible" to the immune system, contributing to acquired resistance. Moreover, the emergence of resistant tumor clones with genetic or epigenetic alterations that promote immune evasion may also contribute to acquired resistance. The lack of reliable predictive biomarkers for patient selection and response monitoring remains a significant challenge in PD-1 targeted immunotherapy. While PD-L1 expression has been explored as a potential biomarker, its utility is limited due to dynamic expression patterns, variability in detection methods, and the presence of PD-L1-negative responders. Additionally, other biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI), have shown promise but require further validation [4]. PD-1 targeted immunotherapy can be associated with a unique spectrum of immune-related adverse events (irAEs), ranging from mild to life-threatening. These adverse events can affect various organ systems, including the skin, gastrointestinal tract, endocrine glands, and lungs. Effective management strategies, including early recognition, appropriate immunosuppressive interventions, and multidisciplinary care, are crucial for mitigating the risks and ensuring patient safety [5].

While PD-1 targeted immunotherapy has demonstrated remarkable efficacy as a monotherapy in certain malignancies, the exploration of combination strategies holds promise for improving clinical outcomes. Ongoing research efforts are focused on combining PD-1 inhibitors with other immunotherapies, such as CTLA-4 inhibitors, or targeted therapies, such as kinase inhibitors or angiogenesis inhibitors. Additionally, the integration of PD-1 targeted immunotherapy with conventional treatments, such as chemotherapy or radiation therapy, is being investigated to enhance therapeutic synergy [6]. Moreover, the high cost of PD-1 targeted immunotherapy remains a significant barrier, limiting access for many patients, particularly in resource-limited settings. Addressing these financial and accessibility barriers is crucial to ensure that these potentially life-saving therapies are available to a broader patient population, irrespective of socioeconomic status or geographic location.

2. Conclusion

PD-1 targeted immunotherapy has transformed the landscape of cancer treatment, offering hope and improved outcomes for many patients. However, addressing the current challenges, including resistance mechanisms, predictive biomarkers, toxicity management, combination strategies, and accessibility barriers, is crucial to maximize the therapeutic potential of these agents and broaden their applicability. Ongoing research efforts focused on elucidating the underlying mechanisms of resistance, developing reliable predictive biomarkers, optimizing combination regimens, and managing immune-related adverse events hold promise for overcoming these limitations. Interdisciplinary collaborations among researchers, clinicians, pharmaceutical companies, and regulatory bodies are essential to accelerate the translation of these findings into clinical practice. Additionally, addressing the financial and accessibility barriers through innovative pricing models, healthcare policies, and global partnerships is paramount to ensuring that the benefits of PD-1 targeted immunotherapy are accessible to a wider patient population, regardless of socioeconomic status or geographic location. While the road ahead is challenging, the remarkable progress achieved thus far in the field of immunotherapy provides a strong foundation for further advancements. With continued dedication and investment in immunotherapy research, we can overcome the current hurdles and unlock the full potential of PD-1 targeted immunotherapy, ultimately improving patient outcomes and quality of life for those affected by cancer [7].

Funding

This work is supported by the Indian Council of Medical Research, New Delhi (Sanction Letter No. 45/24/2022-/BIO/BMS) and UGC-BSR Grant No-F-30-377/2017(BSR).

Acknowledgment

Mohd Mustafa and Safia Habib express their sincere appreciation to the Indian Council of Medical Research, New Delhi, for the financial assistance provided for [Project ID No. 2021-13007] and UGC-BSR Grant No-F-30-377/2017(BSR).

References

1. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. *Science, 359*(6382), 1350-1355.
2. Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018). Mechanisms of resistance to immune checkpoint inhibitors. *British journal of cancer, 118*(1), 9-16.
3. Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., ... & Ribas, A. (2017). Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. *Cancer discovery, 7*(2), 188-201.
4. Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., ... & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. *Nature reviews Clinical oncology, 18*(6), 345-362.
5. Wang, D. Y., Salem, J. E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., ... & Johnson, D. B. (2018). Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. *JAMA oncology, 4*(12), 1721-1728.
6. Huang, A. C., Orlowski, R. J., Xu, X., Mick, R., George, S. M., Yan, P. K., ... & Mitchell, T. C. (2019). A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nature medicine, 25*(3), 454-461.
7. Bach, P. B., & Conti, R. M. (2017). The high cost of precision cancer medicine. JAMA, 318(19), 1861-1862.



Schematic Diagram

T-cell expresses programmed cell death protein (PD-1) which binds to programmed death ligand 1 (PD-L1) expressed by tumour cells, which prevent the killing of tumour cells, so keeping immune responses in check. By blocking the binding of PD-1 and PD-L1 by tumour inhibitors helps T cells to kill tumour cell. However, there are still challenges for the effective immune therapy and cancer treatment, these challenges include intrinsic and acquired resistance (like antigen presentation, immune dysfunction etc), predictive biomarkers and patient selection, immune related adverse events, combination strategy, financial and accessibility barriers.

Copyright: *©2024 Sidra Islam, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*